Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Changing OTC Business Strategy, Priority Shifts to Volume Retailers
January 15, 2001
- Welfide Transfers Infusion Fluid Business to Otsuka Pharmaceutical Factory, Inc
January 15, 2001
- OTC news on brief
January 15, 2001
- Suntory, Taisho to Codevelop SUN N8075 for Cerebral Infarction
January 15, 2001
- The Year 2000 in RetrospectJapanese Drug Industry at the Mercy of Large Waves of Globalization
January 1, 2001
- CST Report Urges Strengthening Lifestyle-related Disease Research
January 1, 2001
- Hitachi to Provide High Tech Healthcare Services
January 1, 2001
- 'New Opportunities and New Solutions Are within Reach'
January 1, 2001
- REGULATORY NEWS IN BRIEF
January 1, 2001
- Siemens-Asahi Medical to Launch New Maintenance-free Spiral CT
January 1, 2001
- PhRMA Japan Representative Moves to Kamiyacho
January 1, 2001
- Kraft: Consolidated Half-year Sales Mark ¥13.5 Bil.
January 1, 2001
- Additional Safety Measures for Bio-Vascular's Artificial Blood Vessel Ordered
January 1, 2001
- Perspective for the Japanese Pharmaceutical Industry in 2001
January 1, 2001
- AstraZeneca K.K.
January 1, 2001
- DIAGNOSTIC NEWS IN BRIEF
January 1, 2001
- Sankyo to Codevelop Oral Antithrombotic with Lilly
January 1, 2001
- Long-term Administration of PPI Included in Insurance Coverage
January 1, 2001
- Aiming at Sales of ¥350 Bil. to ¥400 Bil. in 2005: Mr Bootes of Pfizer
January 1, 2001
- Mitsubishi-Tokyo Licenses Antiviral Agent MCC-478 to Eli Lilly
January 1, 2001
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…